KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amgen (AMGN) Capital Expenditures (2016 - 2025)

Amgen has reported Capital Expenditures over the past 17 years, most recently at $642.0 million for Q4 2025.

  • Quarterly results put Capital Expenditures at $642.0 million for Q4 2025, up 73.05% from a year ago — trailing twelve months through Dec 2025 was $1.9 billion (up 69.53% YoY), and the annual figure for FY2025 was $1.9 billion, up 69.53%.
  • Capital Expenditures for Q4 2025 was $642.0 million at Amgen, up from $436.0 million in the prior quarter.
  • Over the last five years, Capital Expenditures for AMGN hit a ceiling of $642.0 million in Q4 2025 and a floor of $160.0 million in Q3 2022.
  • Median Capital Expenditures over the past 5 years was $253.0 million (2023), compared with a mean of $294.1 million.
  • Biggest five-year swings in Capital Expenditures: tumbled 33.88% in 2022 and later surged 81.05% in 2023.
  • Amgen's Capital Expenditures stood at $287.0 million in 2021, then increased by 18.47% to $340.0 million in 2022, then fell by 26.76% to $249.0 million in 2023, then surged by 49.0% to $371.0 million in 2024, then soared by 73.05% to $642.0 million in 2025.
  • The last three reported values for Capital Expenditures were $642.0 million (Q4 2025), $436.0 million (Q3 2025), and $369.0 million (Q2 2025) per Business Quant data.